Pulmonx Corporation (LUNG) DCF Valuation

Pulmonx Corporation (LUNG) DCF Valuation
  • ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
  • ✓ Design Profissional: Modelos Confiáveis ​​E Padrão Da Indústria
  • ✓ Pré-Construídos Para Uso Rápido E Eficiente
  • ✓ Não É Necessária Experiência; Fácil De Seguir

Pulmonx Corporation (LUNG) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Discover the true potential of Pulmonx Corporation (LUNG) with our advanced DCF Calculator! Adjust key assumptions, explore various scenarios, and assess how changes affect Pulmonx Corporation's valuation – all within a single Excel template.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 32.6 32.7 48.4 53.7 68.7 83.6 101.9 124.1 151.1 184.0
Revenue Growth, % 0 0.42338 47.91 10.84 27.98 21.79 21.79 21.79 21.79 21.79
EBITDA -16.8 -28.4 -46.6 -56.0 -55.1 -69.4 -84.5 -103.0 -125.4 -152.7
EBITDA, % -51.61 -86.88 -96.29 -104.34 -80.22 -83 -83 -83 -83 -83
Depreciation 1.2 .4 3.2 4.0 1.9 3.6 4.4 5.4 6.6 8.0
Depreciation, % 3.68 1.22 6.53 7.45 2.84 4.34 4.34 4.34 4.34 4.34
EBIT -18.0 -28.8 -49.8 -60.0 -57.0 -71.3 -86.9 -105.8 -128.9 -156.9
EBIT, % -55.29 -88.1 -102.82 -111.79 -83.06 -85.29 -85.29 -85.29 -85.29 -85.29
Total Cash 28.3 231.6 180.0 141.1 117.1 81.5 99.2 120.8 147.1 179.2
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 6.0 4.2 6.6 8.7 12.1
Account Receivables, % 18.4 12.92 13.55 16.17 17.63
Inventories 5.6 10.7 16.3 14.6 16.7 22.6 27.5 33.5 40.8 49.7
Inventories, % 17.22 32.81 33.64 27.14 24.38 27.04 27.04 27.04 27.04 27.04
Accounts Payable 2.7 1.5 1.6 1.8 1.5 3.6 4.4 5.3 6.5 7.9
Accounts Payable, % 8.23 4.5 3.27 3.28 2.18 4.29 4.29 4.29 4.29 4.29
Capital Expenditure -.7 -.9 -3.7 -1.3 -.8 -2.7 -3.3 -4.0 -4.9 -6.0
Capital Expenditure, % -2.21 -2.78 -7.58 -2.46 -1.18 -3.24 -3.24 -3.24 -3.24 -3.24
Tax Rate, % -0.94737 -0.94737 -0.94737 -0.94737 -0.94737 -0.94737 -0.94737 -0.94737 -0.94737 -0.94737
EBITAT -18.3 -29.0 -50.1 -60.4 -57.6 -71.3 -86.9 -105.8 -128.9 -156.9
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -26.8 -34.1 -58.4 -57.9 -62.3 -75.2 -92.8 -113.0 -137.6 -167.6
WACC, % 7.7 7.7 7.7 7.7 7.7 7.7 7.7 7.7 7.7 7.7
PV UFCF
SUM PV UFCF -458.2
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) -171
Terminal Value -3,001
Present Terminal Value -2,071
Enterprise Value -2,529
Net Debt -42
Equity Value -2,487
Diluted Shares Outstanding, MM 38
Equity Value Per Share -65.50

What You Will Get

  • Pre-Filled Financial Model: Pulmonx Corporation’s actual data provides accurate DCF valuation.
  • Full Forecast Control: Modify revenue growth, profit margins, WACC, and other essential metrics.
  • Instant Calculations: Real-time updates ensure you see outcomes as you implement changes.
  • Investor-Ready Template: A polished Excel file crafted for high-quality valuation.
  • Customizable and Reusable: Designed for adaptability, allowing repeated application for comprehensive forecasts.

Key Features

  • Comprehensive Data: Pulmonx Corporation's historical financial statements and pre-filled projections.
  • Customizable Parameters: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
  • Real-Time Insights: Instantly view Pulmonx's intrinsic value recalculating on demand.
  • Visual Data Representation: Dashboard graphs illustrate valuation outcomes and essential metrics.
  • Designed for Precision: A reliable tool tailored for analysts, investors, and finance professionals.

How It Works

  • Step 1: Download the prebuilt Excel template featuring Pulmonx Corporation’s (LUNG) data.
  • Step 2: Navigate through the pre-filled sheets to familiarize yourself with the essential metrics.
  • Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
  • Step 4: Instantly see the recalculated results, including Pulmonx Corporation’s intrinsic value.
  • Step 5: Utilize the outputs to make informed investment decisions or create reports.

Why Choose Pulmonx Corporation (LUNG)?

  • Innovative Solutions: Cutting-edge technology for lung health improvement.
  • Proven Results: Backed by clinical studies demonstrating effectiveness.
  • Patient-Centric: Focused on enhancing patient quality of life through advanced treatments.
  • Expertise: Developed by a team of industry leaders and medical professionals.
  • Accessible Information: Comprehensive resources available for patients and healthcare providers.

Who Should Use This Product?

  • Investors: Evaluate Pulmonx Corporation’s (LUNG) market position before making investment decisions.
  • CFOs and Financial Analysts: Optimize valuation methods and assess financial forecasts for Pulmonx Corporation.
  • Startup Founders: Gain insights into how companies like Pulmonx Corporation are valued in the healthcare sector.
  • Consultants: Create detailed valuation reports to assist clients in understanding Pulmonx Corporation’s worth.
  • Students and Educators: Utilize real-time data from Pulmonx Corporation to explore and teach valuation strategies.

What the Template Contains

  • Pre-Filled DCF Model: Pulmonx Corporation’s (LUNG) financial data preloaded for immediate use.
  • WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
  • Financial Ratios: Evaluate Pulmonx Corporation’s (LUNG) profitability, leverage, and efficiency.
  • Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
  • Financial Statements: Annual and quarterly reports to support detailed analysis.
  • Interactive Dashboard: Easily visualize key valuation metrics and results.

No products were found matching.